Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary
Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.
How this was made

The 30-second read
Why it matters
The earnings release confirms continued R&D spend with no commercial revenue, likely pressuring the stock.
Market read
Micro‑cap biotech earnings with no revenue; relevant for traders tracking early‑stage biotech risk.
What to watch
Partnerships with MGH/Harvard and Tesla Dynamic Coils could de‑risk future trials.
Background
Alzamend Neuro is a clinical‑stage neuro‑technology company developing AL001 and ALZN002.
Ticker impact
Alzamend Neuro filed its Q1 2027 10‑Q showing a $3.03M net loss and no product revenue.
Potential short‑term downside pressure as investors digest the loss.
Micro‑cap biotech earnings often move sharply on cash‑flow results; no revenue and a larger loss suggest heightened risk.
Market effects
Highlights ongoing funding challenges for early‑stage neuro‑tech firms.
Limited to US biotech niche; no broader market effect.
Minimal, as the company is a micro‑cap with niche focus.
Counterpoint
If the Phase II data prove compelling, the loss may be viewed as a temporary investment in pipeline value.
Key entities
- companyAlzamend Neuro, Inc.
Clinical‑stage neuro‑technology firm.